top of page

Insights and News Curated for Life Science Experts by Life Science Experts....

Go back to...
JMG Logo transparent.png
Executive Spotlights

Beacon Therapeutics Secures $170M in Series B Funding to Accelerate Progress in Ophthalmic Gene Therapy Development

  • Jul 3, 2024
  • 1 min read

London and Cambridge, MA, July 3, 2024 (PRNewswire) -- Beacon Therapeutics has raised $170 million in Series B funding to advance its ophthalmic gene therapy initiatives, supported by Forbion and other investors. The funding will expedite development of AGTC-501 and other pipeline projects, while new appointments strengthen the company's board governance.


Read full article here.

 
 
 

Recent Posts

See All
LIXTE Names Sidney Braun CEO of Liora Technologies

Boca Raton, FL, February 18, 2026 (Globe Newswire) -- LIXTE Biotechnology Holdings, Inc., a clinical-stage oncology company developing small-molecule cancer therapies and radiotherapy technologies,

 
 
 

Comments


Life Science Headlines
bottom of page